| Name | Title | Contact Details |
|---|
Techmotive is a tech-enabled service provider established in 2012, based in Oahu, Hawaii. Our company specializes in re-calibrating Advanced Driver Assistance Systems (ADAS) for vehicles, primarily for collision centers. ADAS are systems within vehicles that assist drivers with driving and parking, enhancing safety and overall driving experience by using sensors, cameras, and software algorithms to monitor surroundings, detect potential hazards, and alert or take corrective actions as needed. With a heritage built on innovation, quality, and trust, Techmotive stands as a leader in the automotive service industry. We invite you to explore our services and experience the difference that Original Equipment (OE) and dedication to excellence can make.
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
I am Eleanor Allen - a proven CEO turned business consultant and coach. I founded Catapult For Change to save you time by offering you surefire success due to my deep experience in business transformations, turnarounds, and growth strategies. Ill guide you to excel in the C-Suite, fostering a personal leadership exploration that uplifts both you and your organization. The inception of Catapult For Change stemmed from my passion to empower executives in unlocking their full potential. I firmly believe in the inherent greatness within each individual; however, obstacles occasionally hinder our progress. Our mission is to guide individuals and teams in overcoming these hurdles through a comprehensive approach to problem-solving and personal growth. This extends to our dedicated support for CEOs and C-Suite leaders, fostering the development of skills and talents that enable them to excel in their roles with both grace and joy. My personal purpose is to enhance the quality of life for both people and the planet, and Catapult For Change serves as my conduit to do this. Operating as a Public Benefit Corporation (PBC), Catapult For Change distinguishes itself by not only functioning similarly to an S Corp or an LLC but also by incorporating a public benefit element. Based in Colorado, Catapult For Change aligns with the PBC criteria by contributing to the philanthropic endeavors of Water For People - an organization I formerly led. Water For People operates globally across nine countries in Latin America, Asia, and Africa, addressing the urgent global water crisis and empowering communities with sustainable access to clean water and sanitation services, with the commitment of Everyone, Forever. Catapult For Change pledges annual donations to support Water For Peoples mission. As a PBC, our commitment to this cause is transparently showcased in our mandatory annual impact report, a requirement for all PBCs filed in the State of Colorado.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.